Go online to PeerView.com/AHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to care for your patients with multiple myeloma (MM) who are experiencing ocular complications associated with the latest myeloma treatments? Ophthalmologists play an important in the care of myeloma, and in this PeerView MasterClass & Ophthalmology Case Forum an ophthalmologist and an oncologist highlight the importance of the ophthalmology and oncology connection in myeloma care. Tune in to get practical guidance on the challenges of accurately recognizing and characterizing ocular toxicity in MM patients receiving novel therapy and case-based guidance on collaborating within a modern MM management team, and see how addressing ocular toxicity can contribute to the delivery of highly effective treatment. Upon completion of this activity, participants should be better able to: Recognize the range of novel, therapy-associated ocular complications in the multiple myeloma treatment setting; Integrate proven techniques, including scheduled and routine eye examinations, dry eye prophylaxis, and therapeutic dose adjustment to address ocular toxicity in patients with multiple myeloma; Work collaboratively within oncology-ophthalmology teams to effectively monitor and manage treatment-emergent ocular toxicity in multiple myeloma patients
View all episodes
